Research and Development Expenses Breakdown: Jazz Pharmaceuticals plc vs Viking Therapeutics, Inc.

R&D Spending: Jazz vs. Viking - A Decade of Growth

__timestampJazz Pharmaceuticals plcViking Therapeutics, Inc.
Wednesday, January 1, 20148518100022223073
Thursday, January 1, 20151352530006966842
Friday, January 1, 20161622970009000499
Sunday, January 1, 201719844200013741186
Monday, January 1, 201822661600019040000
Tuesday, January 1, 201929972600023559000
Wednesday, January 1, 202033537500031931000
Friday, January 1, 202150574800044981000
Saturday, January 1, 202259045300054234000
Sunday, January 1, 202384965800063806000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: R&D Spending Trends

In the competitive world of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Jazz Pharmaceuticals plc and Viking Therapeutics, Inc. have shown contrasting trajectories in their R&D investments over the past decade.

From 2014 to 2023, Jazz Pharmaceuticals has consistently increased its R&D expenses, culminating in a staggering 900% growth by 2023. This reflects their aggressive strategy to expand their drug pipeline and enhance their market position. In contrast, Viking Therapeutics, while also increasing its R&D spending, has done so at a more modest pace, with a 187% rise over the same period.

These trends highlight the differing scales and strategies of these two companies, with Jazz Pharmaceuticals taking a more expansive approach compared to the more cautious, yet steady, path of Viking Therapeutics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025